I want to start a new thread about this company! I know that not a lot is known about it, since it's a small private company. It seems to me that they are written off as insignificant too easily!
However, the founder of this company - Prof. Dr. Hubert Löwenheim - is a senior clinician and researcher with focus on otology and neurotology. He was the first to describe the involvement of cell cycle regulators, especially p27Kip1, in the proliferation and differentiation of hair cells and supporting cells in the cochlea.
In 1998, he founded a company called Otogene AG with the aim to identify an inhibitor of p27Kip1 as a regenerative drug. He also founded Otogene Inc. in Seattle as a subsidiary of Otogene AG. In 2002, Otogen AG ceased its operation, but the US company has continued its operation and is now known as Sound Pharmaceuticals Inc.
Acousia is involved in the EU funded Regain project (ID 634893, EU contribution 5834340 EUR), as well as the Otostem project (ID 603029, EU contribution 5999784 EUR).
Professor Löwenheim is assigned to be the coordinator of the Otostem project. There have been several EU funded projects aimed at hearing restoration over the years, but this might be the biggest one so far. It's international too, because we have the US involved. We find several familiar names here, like Albert Edge from Massachusetts Eye and Ear, one of the founders of Decibel Therapeutics. We also find Stanford university on board, where we know professor Stefan Heller and his team is working on bringing back hearing for millions of people under the so called SICHL initiative.
Other names I want to mention only briefly is professor Helge Rask Andersen from Uppsala university (the only place in Sweden where you will find regenerative research efforts concerning the inner ear), and Rolf Jan Rutten who is the founder of Audion Therapeutics.
Professor Hubert Löwenheim is in it too deep to be neglected as insignificant. After all, he has been selected to lead this project, with all these big names in the field. So with this thread, I want to give the man some credit and recognition for his 20 years of dedicated work in inner ear regeneration. His company may be small and private at the moment, as most startup companies are. But I hope we will hear from this company very soon.
However, the founder of this company - Prof. Dr. Hubert Löwenheim - is a senior clinician and researcher with focus on otology and neurotology. He was the first to describe the involvement of cell cycle regulators, especially p27Kip1, in the proliferation and differentiation of hair cells and supporting cells in the cochlea.
In 1998, he founded a company called Otogene AG with the aim to identify an inhibitor of p27Kip1 as a regenerative drug. He also founded Otogene Inc. in Seattle as a subsidiary of Otogene AG. In 2002, Otogen AG ceased its operation, but the US company has continued its operation and is now known as Sound Pharmaceuticals Inc.
Acousia is involved in the EU funded Regain project (ID 634893, EU contribution 5834340 EUR), as well as the Otostem project (ID 603029, EU contribution 5999784 EUR).
Professor Löwenheim is assigned to be the coordinator of the Otostem project. There have been several EU funded projects aimed at hearing restoration over the years, but this might be the biggest one so far. It's international too, because we have the US involved. We find several familiar names here, like Albert Edge from Massachusetts Eye and Ear, one of the founders of Decibel Therapeutics. We also find Stanford university on board, where we know professor Stefan Heller and his team is working on bringing back hearing for millions of people under the so called SICHL initiative.
Other names I want to mention only briefly is professor Helge Rask Andersen from Uppsala university (the only place in Sweden where you will find regenerative research efforts concerning the inner ear), and Rolf Jan Rutten who is the founder of Audion Therapeutics.
Professor Hubert Löwenheim is in it too deep to be neglected as insignificant. After all, he has been selected to lead this project, with all these big names in the field. So with this thread, I want to give the man some credit and recognition for his 20 years of dedicated work in inner ear regeneration. His company may be small and private at the moment, as most startup companies are. But I hope we will hear from this company very soon.